Nektar Therapeutics (NKTR) EBIAT: 2010-2025
Historic EBIAT for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to -$35.5 million.
- Nektar Therapeutics' EBIAT rose 4.14% to -$35.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$120.7 million, marking a year-over-year increase of 28.26%. This contributed to the annual value of -$119.0 million for FY2024, which is 56.91% up from last year.
- Per Nektar Therapeutics' latest filing, its EBIAT stood at -$35.5 million for Q3 2025, which was up 14.60% from -$41.6 million recorded in Q2 2025.
- Nektar Therapeutics' EBIAT's 5-year high stood at $7.3 million during Q4 2024, with a 5-year trough of -$159.1 million in Q2 2022.
- In the last 3 years, Nektar Therapeutics' EBIAT had a median value of -$42.1 million in 2023 and averaged -$47.5 million.
- Per our database at Business Quant, Nektar Therapeutics' EBIAT crashed by 56.90% in 2021 and then spiked by 117.26% in 2024.
- Quarterly analysis of 5 years shows Nektar Therapeutics' EBIAT stood at -$145.6 million in 2021, then soared by 59.02% to -$59.7 million in 2022, then increased by 29.50% to -$42.1 million in 2023, then surged by 117.26% to $7.3 million in 2024, then grew by 4.14% to -$35.5 million in 2025.
- Its EBIAT was -$35.5 million in Q3 2025, compared to -$41.6 million in Q2 2025 and -$50.9 million in Q1 2025.